Clexane 40 mg/0.4 ML 2 Prefilled Syringe

Anticoagulant belongs to low molecular weight heparins; used in the treatment of ischemic heart disease, injected into arterial line of hemodialysis circuit to prevent coagulation and used for the treatment and prophylaxis against venous thromboembolism.

- Deep Vein Thrombosis (Prophylaxis; 40 mg SC qDay, Treatment; 1 mg/kg SC q12hr, OR 1.5 mg/kg SC qDay) - Unstable Angina & Non-Q-Wave MI. (1 mg/kg SC q12hr) - Acute Coronary Syndromes. (Loading dose: 30 mg IV bolus once plus 1 mg/kg SC once, Maintenance: 1 mg/kg SC q12hr)

- Hemorrhage (1-4%) - Elevation of serum aminotransferases (6%) - Fever (5-8%) - Local site reactions (2-5%) - Thrombocytopenia (3%) - Nausea (3%) - Anemia (2%) - Ecchymosis (3%) - Hyperkalemia. - Osteoporosis following long-term therapy.

- Black Box Warnings Epidural or spinal hematomas may occur in patients anticoagulated with low-molecular-weight heparin (LMWH) or heparinoids who receive neuraxial (epidural/spinal) anesthesia or spinal puncture. - Bleeding may occur; monitor patients with risk factors, including congenital or acquired bleeding disorders. - Monitor for hyperkalemia (possibly from aldosterone suppression). - Enoxaparin-induced thrombocytopenia and thrombosis reported; use extreme caution or avoid in patients with history heparin induced thrombocytopenia (HIT).

Store below 25ºC. Do not freeze. Store it in a cool, dry place away from moisture, heat or sunlight.

- Contraindicated (3) defibrotide mifepristone prothrombin complex concentrate, human. - Serious abciximab anagrelide antithrombin alfa antithrombin III apixaban argatroban azithromycin bazedoxifene/conjugated estrogens bemiparin bivalirudin butalbital - Monitor Closely acalabrutinib aceclofenac acemetacin agrimony alfalfa alteplase American ginseng amiloride anamu aspirin

- Human data from a retrospective cohort study, suggest that enoxaparin does not increase risk of major developmental abnormalities. - Excretion in milk unknown; not recommended.

SANOFI AVENTIS